Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Nkarta, Inc. develops allogeneic, off-the-shelf natural killer (NK) cell therapies targeting autoimmune diseases and cancers. Its proprietary platform engineers NK cells with enhanced recognition, persistence, and cryopreservation capabilities. The company’s lead candidate, NKX019, targets CD19-positive B cells to treat autoimmune conditions like lupus and scleroderma. Focused on scalable manufacturing and innovative cell engineering, Nkarta aims to provide broadly accessible, disease-modifying immunotherapies.
This description was generated via AI from an annual report. Updated about 1 year ago.